TAKE ACTION NOW.
Sign Up for NotWorthLess Alerts!
ALERT // The Institute for Clinical and Economic Review (ICER) is drawing opposition for its latest report on the “value” of treatments for Duchenne muscular dystrophy. ICER has been criticized by watchdog groups for using a framework that values the lives of patients with rare diseases as less than other patients. While ICER’s latest report targets Duchenne patients, it has issued reports on treatments for everything from migraines to cancer, and many more conditions are on ICER’s agenda for next year.